References of "Revue Médicale Suisse"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailIntérêt du dépistage et du traitement de l'acidose métabolique chez l'insuffisant rénal chronique
Georges, benoit; Huart, Justine ULiege; KRZESINSKI, Jean-Marie ULiege et al

in Revue Médicale Suisse (2018), 14(1455-1458),

L’acidose métabolique est une anomalie biologique fréquente et précoce de l’insuffisance rénale chronique (IRC). Les complications liées à cet état sont multiples et touchent notamment l’os, le muscle et ... [more ▼]

L’acidose métabolique est une anomalie biologique fréquente et précoce de l’insuffisance rénale chronique (IRC). Les complications liées à cet état sont multiples et touchent notamment l’os, le muscle et le métabolisme protidique, sans parler du risque accru d’hyperkaliémie. Une causalité entre acidose métabolique et accélération du déclin rénal a été démontrée. La mesure du taux de bicarbonate sérique doit, dès lors, faire partie du suivi biologique systématique du patient en IRC dont le taux de filtration glomérulaire s’abaisse en dessous de 50 ml/min/1,73 m². Le dépistage et le traitement de l’acidose métabolique sont en effet simples et peu coûteux. La correction de l’acidose métabolique, notamment par le bicarbonate de sodium, permet de ralentir la progression de l’insuffisance rénale. [less ▲]

Detailed reference viewed: 16 (1 ULiège)
Full Text
Peer Reviewed
See detailAdenocarcinome obstructif localement avance de la tete du pancreas : importance du drainage biliaire precoce.
Deflandre, Laure-Anne; LOLY, Jean-Philippe ULiege; LECLERCQ, Philippe ULiege et al

in Revue Médicale Suisse (2018), 14(615), 1443-1447

The incidence of pancreatic cancer is increasing, but proportion of resectable cases and survival do not increase. Then, our care strategies have to be optimized. Chemotherapy is the principal treatment ... [more ▼]

The incidence of pancreatic cancer is increasing, but proportion of resectable cases and survival do not increase. Then, our care strategies have to be optimized. Chemotherapy is the principal treatment of locally advanced pancreatic cancer. When the tumour triggers biliary obstruction, chemotherapy-associated morbidity increases, and biliary drainage becomes crucial. Gold-standard is endoscopic retrograde cholangiography, which could be impossible when duodenum or papilla are involved by the tumour. Other options are percutaneous radiologic drainage, surgical double by-pass or EUS-guided drainage. When EUS-guided procedures are available, they are proposed today as the best options. [less ▲]

Detailed reference viewed: 16 (1 ULiège)
Full Text
Peer Reviewed
See detailNouveautes dans la prise en charge du myelome.
Vrancken, Louise; Muller, Joséphine ULiege; Lejeune, Margaux ULiege et al

in Revue Médicale Suisse (2018), 14(615), 1438-1442

Multiple myeloma is the second most frequent hematological malignancy. Unfortunately, it is still incurable. A better understanding of the myeloma pathophysiology favored the development of new ... [more ▼]

Multiple myeloma is the second most frequent hematological malignancy. Unfortunately, it is still incurable. A better understanding of the myeloma pathophysiology favored the development of new therapeutic molecules that improved both survival and quality of life of patients. Diagnostic and prognostic criteria for myeloma have been reviewed and help to detect multiple myeloma more early and further help to define the best therapeutic strategy. These new regimens are associated with side effects that differ from those of classic molecules and that we have to be able to recognize and to treat appropriately. [less ▲]

Detailed reference viewed: 51 (12 ULiège)
Full Text
Peer Reviewed
See detailSécurité cardiovasculaire des inhibiteurs de la DPP-4 comparée à celle des sulfamides hypoglycémiants
Scheen, André ULiege

in Revue Médicale Suisse (2018), 14(615), 1468-1472

After metformin monotherapy, the choice between a sulfonylurea and a dipeptidyl peptidase-4 (DPP-4) inhibitor may be critical in clinical practice. This article compares the cardiovascular safety of these ... [more ▼]

After metformin monotherapy, the choice between a sulfonylurea and a dipeptidyl peptidase-4 (DPP-4) inhibitor may be critical in clinical practice. This article compares the cardiovascular safety of these two pharmacological classes based on meta-analyses of randomized controlled trials and observational studies. Both approaches show a better cardiovascular safety with DPP-4 inhibitors than with sulfonylureas. However, some heterogeneity exists, most probably explained by differences between the molecules, especially among sulfonylureas as those of last generation (more particularly gliclazide) seem to have a better safety profile. The ongoing head-to-head prospective trial CAROLINA compares the cardiovascular safety of glimepiride and linagliptin in high-risk patients, with results expected in 2019. © 2018 Editions Medecine et Hygiene. All rights reserved. [less ▲]

Detailed reference viewed: 26 (1 ULiège)
Full Text
Peer Reviewed
See detailL’hôpital comme espace et comme territoire
Stiefel, Friedrich; Marion-Veyron, Régis; Englebert, Jérôme ULiege

in Revue Médicale Suisse (2018), 593(14), 324-326

Space is lived individually and collectively and can become a source of existential affectation, especially when the lived experience is modified by disease. The fact that the hospital is also a place of ... [more ▼]

Space is lived individually and collectively and can become a source of existential affectation, especially when the lived experience is modified by disease. The fact that the hospital is also a place of territorialisation can potentiate this affectation, with at times surprizing consequences. We aim –based on a reflection about the relationship patients and clinicians establish with the territory of the hospital- to identify some psychological and existential issues at stake with regard to space as a social construction. [less ▲]

Detailed reference viewed: 92 (12 ULiège)
Full Text
Peer Reviewed
See detailPharmacothérapie: éviter l’empilement et penser à la désescalade!
Scheen, André ULiege

in Revue Médicale Suisse (2018), 14(615), 1435-1436

[No abstract available]

Detailed reference viewed: 17 (2 ULiège)
Full Text
Peer Reviewed
See detailSecurite cardiovasculairedes inhibiteurs de la DPP-4 compareea celle des sulfamides hypoglycemiants.
Scheen, André ULiege

in Revue Médicale Suisse (2018), 14(615), 1468-1472

After metformin monotherapy, the choice between a sulfonylurea and a dipeptidyl peptidase-4 (DPP-4) inhibitor may be critical in clinical practice. This article compares the cardiovascular safety of these ... [more ▼]

After metformin monotherapy, the choice between a sulfonylurea and a dipeptidyl peptidase-4 (DPP-4) inhibitor may be critical in clinical practice. This article compares the cardiovascular safety of these two pharmacological classes based on meta-analyses of randomized controlled trials and observational studies. Both approaches show a better cardiovascular safety with DPP-4 inhibitors than with sulfonylureas. However, some heterogeneity exists, most probably explained by differences between the molecules, especially among sulfonylureas as those of last generation (more particularly gliclazide) seem to have a better safety profile. The ongoing head-to-head prospective trial CAROLINA compares the cardiovascular safety of glimepiride and linagliptin in high-risk patients, with results expected in 2019. [less ▲]

Detailed reference viewed: 106 (3 ULiège)
Full Text
Peer Reviewed
See detailInhibiteur des SGLT2 ou analogue du GLP-1 chez un patient diabetique avec maladie cardiovasculaire ?
Scheen, André ULiege; Paquot, Nicolas ULiege

in Revue Médicale Suisse (2018), 14(615), 1460-1465

Sodium-glucose cotransporter type 2 inhibitors (SGLT2is), with empagliflozin in EMPA-REG OUTCOME, and glucagon-like peptide-1 receptor agonists (GLP-1RAs), with liraglutide in LEADER, have proven their ... [more ▼]

Sodium-glucose cotransporter type 2 inhibitors (SGLT2is), with empagliflozin in EMPA-REG OUTCOME, and glucagon-like peptide-1 receptor agonists (GLP-1RAs), with liraglutide in LEADER, have proven their ability to reduce major cardiovascular events and mortality in patients with type 2 diabetes and established cardiovascular disease. Thus clinicians have to choose between the two options in patients at high risk. The choice should be based upon a personalized approach, which has to take into account the drug properties, especially the tolerance profile, and patient's individual characteristics. In patients with heart failure, the added value of a SGLT2i appears obvious while in those with advanced renal insufficiency, current evidence favours the use of a GLP-1RA. [less ▲]

Detailed reference viewed: 38 (1 ULiège)
Full Text
Peer Reviewed
See detailInhibiteurs de la pompe à protons et risque d'insuffisance rénale
PAQUOT, Francois ULiege; Krzesinski, Jean-Marie ULiege

in Revue Médicale Suisse (2017)

Regarded as safe and effective for management of upper peptic ulcer disease due to gastric acid secretion, the proton pump inhibitors are among the most commonly prescribed drugs. Their use, however, is ... [more ▼]

Regarded as safe and effective for management of upper peptic ulcer disease due to gastric acid secretion, the proton pump inhibitors are among the most commonly prescribed drugs. Their use, however, is not without concerns. Acute kidney injury, mainly due to acute interstitial nephritis, could happen 1.5 to 2 times more frequently when using these drugs. Moreover, a risk for chronic kidney disease has also be noted with proton pump inhibitor use (1.15 to 1.8 increased risk), although biases may exist due to confounding factors related to the observational nature of the studies. So, caution is required before available results from good prospective randomized studies are available. Renal function should be checked when using these medications and timely cessation should be advised when there is no more clear indication for use. [less ▲]

Detailed reference viewed: 96 (18 ULiège)
Full Text
Peer Reviewed
See detailProtection cardio-renale par les inhibiteurs des SGLT2 (gliflozines) : d'EMPA-REG OUTCOME a CANVAS.
Scheen, André ULiege; Ernest, Philippe; Jandrain, Bernard

in Revue Médicale Suisse (2017), 13(571), 1421-1426

The cardiovascular (CV) and renal protection reported with empagliflozin in EMPA-REG OUTCOME is now confirmed with canagliflozin in CANVAS in patients with type 2 diabetes and high cardiovascular risk ... [more ▼]

The cardiovascular (CV) and renal protection reported with empagliflozin in EMPA-REG OUTCOME is now confirmed with canagliflozin in CANVAS in patients with type 2 diabetes and high cardiovascular risk: similar and significant reductions in major CV events (-14 vs. -14%), in hospitalisations for heart failure (-35 vs. -33%) and in renal events (-39 vs. -40%). The greater reduction in CV mortality (-38 vs. - 13%) and all-cause mortality (-32 vs. -13%) in EMPA-REG OUTCOME than in CANVAS may be explained by the greater proportion of patients with CV disease (secondary prevention : 99 vs. 65%). In contrast to EMPA-REG OUTCOME, CANVAS did not show an increase in stroke (-10%, NS), but reported a higher rate of fractures and amputations with canagliflozin. Overall, these results support a class effect for the cardiorenal protection by inhibitors of sodium-glucose type 2 (SGLT2) cotransporters. [less ▲]

Detailed reference viewed: 728 (6 ULiège)
Full Text
Peer Reviewed
See detailOstéoporose et sarcopénie: convergences et divergences
Reginster, Jean-Yves ULiege

in Revue Médicale Suisse (2017), 13(547), 184-185

[No abstract available]

Detailed reference viewed: 26 (1 ULiège)
Full Text
Peer Reviewed
See detailEndomicroscopie confocale dans la prise en charge des maladies inflammatoires chroniques de l'intestin.
LOLY, Jean-Philippe ULiege; SOMJA, Joan ULiege; REENAERS, Catherine ULiege et al

in Revue Médicale Suisse (2017), 13(571), 1431-1434

Inflammatory bowel diseases are chronic diseases whose long-term evolution depends on the depth of remission. Their clinical and endoscopic evaluation is imperfect. The development of confocal ... [more ▼]

Inflammatory bowel diseases are chronic diseases whose long-term evolution depends on the depth of remission. Their clinical and endoscopic evaluation is imperfect. The development of confocal endomicroscopy allows microscopic images to be obtained in vivo. These microscopic data are correlated with the activity of the disease. They predict a possible relapse of the disease and also predict the response to treatment with a biological agent, which allows to modify the therapy before the relapse or to make a rational choice between the different biological agents before introducing a new treatment. [less ▲]

Detailed reference viewed: 100 (9 ULiège)
Full Text
Peer Reviewed
See detailPourquoi traiter une occlusion coronaire totale chronique ?
MARECHAL, Patrick ULiege; GACH, Olivier ULiege; DAVIN, Laurent ULiege et al

in Revue Médicale Suisse (2017), 13(571), 1406-1409

Despite an incidence of about 15% of the patients undergoing coronary angiography, total chronic occlusions (CTO) are rarely revascularized by percutaneous angioplasty (PCI). Nevertheless, current ... [more ▼]

Despite an incidence of about 15% of the patients undergoing coronary angiography, total chronic occlusions (CTO) are rarely revascularized by percutaneous angioplasty (PCI). Nevertheless, current evidence suggest that successful CTO-PCI improve symptoms, quality of live and long-term survival. During the last years, improvement of specific techniques for these complexes procedures and increasing experience of operators allow actually to obtain success and complications rates almost equivalent to non-CTO lesions angioplasty. This review focus on the clinical benefits of CTO revascularization and on appropriate patient selection. [less ▲]

Detailed reference viewed: 62 (2 ULiège)
Full Text
Peer Reviewed
See detailInhibiteur de la DPP-4 ou des SGLT2 apres echec de la metformine seule dans le diabete de type 2.
Paquot, Nicolas ULiege; Scheen, André ULiege

in Revue Médicale Suisse (2017), 13(571), 1410-1415

After failure of a monotherapy with metformin, dipeptidyl peptidase-4 inhibitors (gliptins) and sodium-glucose cotransporters type 2 (gliflozins) offer an alternative to the add-on of a sulphonylurea ... [more ▼]

After failure of a monotherapy with metformin, dipeptidyl peptidase-4 inhibitors (gliptins) and sodium-glucose cotransporters type 2 (gliflozins) offer an alternative to the add-on of a sulphonylurea, especially in diabetic patients at risk of hypoglycaemia. The choice between a gliptin and a gliflozin may be guided by the individual patient characteristics : rather a gliptin in a patient without obesity or severe hyperglycaemia, in an elderly patient, with a frailty profile or with renal impairment; rather a gliflozin in an obese patient, with hypertension, hyperuricaemia, antecedents of cardiovascular disease (especially heart failure), without advanced renal insufficiency and with a low risk of urinary/genital infections or events linked to dehydration such as hypotension. [less ▲]

Detailed reference viewed: 164 (6 ULiège)
Full Text
Peer Reviewed
See detailOptions therapeutiques chez un patient diabetique de type 2 mal controle par une insuline basale.
Scheen, André ULiege; Paquot, Nicolas ULiege

in Revue Médicale Suisse (2017), 13(571), 1416-1420

In a patient with type 2 diabetes not well controlled with a basal insulin - metformin combination, several therapeutic options may be considered: intensifying insulin therapy with different schemes ... [more ▼]

In a patient with type 2 diabetes not well controlled with a basal insulin - metformin combination, several therapeutic options may be considered: intensifying insulin therapy with different schemes (appropriate titration using a more favourable basal insulin analogue, adding one, two or three rapid-acting insulin analogues, shift to two or three premix insulin injections), adding a dipeptidyl peptidase-4 inhibitor (gliptin) or an inhibitor of sodium-glucose cotransporters type 2 (gliflozin), or combining a glucagon-like peptide-1 receptor agonist with basal insulin. The choice should be made according the individual profile and preference of the patient, in a personalized approach, taking into account the advantages and disadvantages of each therapeutic solution. [less ▲]

Detailed reference viewed: 75 (4 ULiège)
Full Text
Peer Reviewed
See detailA propos du concept de pharmacorésistance
Scheen, André ULiege

in Revue Médicale Suisse (2017), 13(571), 1403-1404

[No abstract available]

Detailed reference viewed: 17 (3 ULiège)
Full Text
Peer Reviewed
See detailEfficacite de trois techniques de chirurgie bariatrique chez des sujets obeses diabetiques de type 2.
Bessemans, Severine; Scheen, André ULiege

in Revue Médicale Suisse (2016), 12(527), 1378-1382

This retrospective work compares the efficacy of three procedures of bariatric surgery in obese patients with type 2 diabetes : gastric bypass (n = 22), sleeve gastrectomy (n = 18) and Magenstrasse & Mill ... [more ▼]

This retrospective work compares the efficacy of three procedures of bariatric surgery in obese patients with type 2 diabetes : gastric bypass (n = 22), sleeve gastrectomy (n = 18) and Magenstrasse & Mill gastroplasty (also known as reversible sleeve (n = 19). The three interventions result in a remarkable weight loss after one year, a better glycaemic control, with often a remission of diabetes, a reduction of blood pressure and an improvement of lipid profile, allowing an interruption or a dose reduction of concomitant medications. Overall, classical sleeve provides almost similar results as gastric bypass and appears slightly better than reversible sleeve. These results deserve confirmation in studies with more patients followed for a longer term. [less ▲]

Detailed reference viewed: 165 (2 ULiège)
Full Text
Peer Reviewed
See detailCombinaison gliptine-gliflozine dans le traitement du diabete de type 2.
Scheen, André ULiege; Paquot, Nicolas ULiege

in Revue Médicale Suisse (2016), 12(527), 1384-1388

Type 2 diabetes (T2D) is a complex disease with multiple defects, which generally require a combination of several pharmacological approaches to control hyperglycaemia. Combining a dipeptidyl peptidase-4 ... [more ▼]

Type 2 diabetes (T2D) is a complex disease with multiple defects, which generally require a combination of several pharmacological approaches to control hyperglycaemia. Combining a dipeptidyl peptidase-4 inhibitor (DPP-4i) and a sodium-glucose cotransporter type 2 inhibitor (SGT2i) appears to be an attractive approach because the two drugs exert different and potentially complementary glucose-lowering effects. Dual therapy (initial combination or stepwise approach) is more potent than either monotherapy in patients treated with diet and exercise or already treated with metformin. Combining the two pharmacological options is safe and does not induce hypoglycaemia. Two fixed-dose combinations (FDCs) are already available (saxagliptin-dapagliflozin and linagliptin-empagliflozin) and others are in current development. [less ▲]

Detailed reference viewed: 237 (4 ULiège)
Full Text
Peer Reviewed
See detailActualité thérapeutique dans le VIH: Le ténofovir alafénamide
SAUVAGE, Anne-Sophie ULiege; DARCIS, Gilles ULiege; Moutschen, Michel ULiege

in Revue Médicale Suisse (2016), 12(527), 1367-1369

Since the first treatments against human immunodeficiency virus (HIV) have appeared in 1987, important progress has been accomplished. Twenty-four molecules are currently available but only some of them ... [more ▼]

Since the first treatments against human immunodeficiency virus (HIV) have appeared in 1987, important progress has been accomplished. Twenty-four molecules are currently available but only some of them are in common use on account of their easy administration or their weak adverse effects. Tenofovir disoproxil fumarate (TDF) is a commonly used nucleoside reverse-transcriptase inhibitor (NRTI) of HIV. However, taking TDF is sometimes associated with renal toxicity and increased bone demineralization. Tenofovir alafenamide (TAF) is a new prodrug of tenofovir (TFV) whose security profile is more interesting as far as renal and bone complications are concerned, due to a much lower serum concentration and a high intracellular concentration. [less ▲]

Detailed reference viewed: 18 (1 ULiège)
Full Text
Peer Reviewed
See detailÉditorial: Chirurgie métabolique versus traitement médical optimize dans la prise en charge du diabète de type 2?
Scheen, André ULiege

in Revue Médicale Suisse (2016), 12(527), 1355-1356

[No abstract available]

Detailed reference viewed: 10 (1 ULiège)